The dynamics of tumour–vasculature interaction suggests low‐dose, time‐dense anti‐angiogenic schedulings

Objectives: The administration schedule appears to be a particularly relevant factor in determining the effectiveness of an antiangiogenic drug. A better quantitative knowledge of the interactions between tumour growth and the development of its vasculature could help to design effective therapies.

[1]  Daniel Tee,et al.  Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies , 2003, Journal of Cancer Research and Clinical Oncology.

[2]  Antonio Fasano,et al.  Dynamics of tumour cords following changes in oxygen availability: A model including a delayed exit from quiescence , 2005, Math. Comput. Model..

[3]  Andreas Friedl,et al.  Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Kerbel,et al.  Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches , 2004, Cancer and Metastasis Reviews.

[5]  Donald W Kufe,et al.  Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[7]  A. d’Onofrio A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.

[8]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[9]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Chaplain,et al.  Continuous and discrete mathematical models of tumor-induced angiogenesis , 1998, Bulletin of mathematical biology.

[11]  J. Folkman Opinion: Angiogenesis: an organizing principle for drug discovery? , 2007, Nature Reviews Drug Discovery.

[12]  T. Wheldon Mathematical models in cancer research , 1988 .

[13]  Alberto Gandolfi,et al.  Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). , 2004, Mathematical biosciences.

[14]  P. Hahnfeldt,et al.  Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. , 2003, Journal of theoretical biology.

[15]  R. D'Amato,et al.  Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.

[16]  Philip Hahnfeldt,et al.  Simple ODE models of tumor growth and anti-angiogenic or radiation treatment , 2001 .

[17]  F. Khuri,et al.  Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Yiannoutsos,et al.  Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  G. Giaccone,et al.  Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  L. Ellis,et al.  Phase I study of recombinant human endostatin in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Sledge,et al.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  John V Heymach,et al.  Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Y. Konishi,et al.  Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. , 1995, Japanese journal of clinical oncology.

[24]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[25]  F. Schramel,et al.  Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  W. Gerald,et al.  A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers , 2006, Investigational New Drugs.

[27]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[28]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[29]  A. Stopeck,et al.  Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Alberto Gandolfi,et al.  A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. , 2008, Mathematical medicine and biology : a journal of the IMA.

[31]  F. Cavalli,et al.  Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Marshall,et al.  A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Eric Masson,et al.  Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  I. B. Borel Rinkes,et al.  Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. , 2000, Cancer research.

[35]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[36]  Peteris Daugulis,et al.  Hopf point analysis for angiogenesis models , 2003 .

[37]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[38]  T. Shankey,et al.  Cell cycle models for molecular biology and molecular oncology: exploring new dimensions. , 1999, Cytometry.

[39]  Yuri Kogan,et al.  Critical-point analysis for three-variable cancer angiogenesis models. , 2005, Mathematical biosciences and engineering : MBE.

[40]  H M Byrne,et al.  Modelling the Role of Angiogenesis and Vasculogenesis in Solid Tumour Growth , 2007, Bulletin of mathematical biology.

[41]  U. Ledzewicz,et al.  ANTI-ANGIOGENIC THERAPY IN CANCER TREATMENT AS AN OPTIMAL CONTROL PROBLEM , 2007 .

[42]  Urszula Ledzewicz,et al.  AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..

[43]  E. Lin,et al.  Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo , 2007 .

[44]  L. Preziosi,et al.  ADVECTION-DIFFUSION MODELS FOR SOLID TUMOUR EVOLUTION IN VIVO AND RELATED FREE BOUNDARY PROBLEM , 2000 .

[45]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[46]  S. Fox,et al.  TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.

[47]  Urszula Foryś,et al.  THREE TYPES OF SIMPLE DDE'S DESCRIBING TUMOR GROWTH , 2007 .

[48]  S. McDougall,et al.  Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. , 2006, Journal of theoretical biology.

[49]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[50]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[51]  J. Rak,et al.  Host microenvironment in breast cancer development: Inflammatory and immune cells in tumour angiogenesis and arteriogenesis , 2003, Breast Cancer Research.

[52]  P. Maini,et al.  A cellular automaton model for tumour growth in inhomogeneous environment. , 2003, Journal of theoretical biology.

[53]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[54]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[55]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[56]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  J. Hainsworth,et al.  A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) , 2005 .

[58]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.